Theravance Biopharma reported its Q1 2021 financial results, highlighting the continued growth of GSK's TRELEGY and the performance of YUPELRI with partner Viatris, despite pandemic-associated headwinds. The company is focused on advancing its pipeline with four significant clinical readouts expected between now and Q1 2022.